SCHEMBL826283

SCHEMBL826283

CC(CCO)C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.84

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.84
KDM4E B2RXH2 1/20 0.84
TDP1 Q9NUW8 1/20 0.71
KMT2A Q03164 7/20 0.66
MEN1 O00255 6/20 0.66
POLB P06746 4/20 0.64
SCN3A Q9NY46 2/20 0.64
SCN1A P35498 1/20 0.64
SCN4A P35499 1/20 0.64
SCN5A Q14524 1/20 0.64
SCN9A Q15858 1/20 0.64
SCN2A Q99250 1/20 0.64
SCN8A Q9UQD0 1/20 0.64
SCN10A Q9Y5Y9 1/20 0.64
LMNA P02545 1/20 0.60
TSHR P16473 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PPIA P62937 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13651636 0.89 ALDH1A1 (0.84) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL10031619 0.89 ALDH1A1 (0.84) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL13865334 0.86 TDP1 (0.67) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL1091645 0.84 TDP1 (0.73) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL15113161 0.83 TDP1 (1.00) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL1102252 0.80 KMT2A (1.00) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL1101958 0.79 MEN1 (0.75) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL13669839 0.79 TDP1 (0.69) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL826391 0.78 SCN3A (0.60) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL183941 0.78 SCN3A (0.60) ALDH1A1KDM4ETDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343763-B2 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-20120149742-A1 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-14 US disclosed
US-8143297-B2 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-27 US disclosed
US-20110098328-A1 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-28 US disclosed
US-7846954-B2 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-07 US disclosed
US-20100004300-A1 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149742-A1 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS TRPV1, KCNJ2, KCNN3 ALDH1A1 1645/4885KDM4E 2958/4885TDP1 3485/4885
US-20100004300-A1 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS TRPV1, KCNJ2, KCNN3 ALDH1A1 1645/4885KDM4E 2958/4885TDP1 3485/4885
US-20110098328-A1 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS TRPV1, KCNJ2, KCNN3 ALDH1A1 1645/4885KDM4E 2958/4885TDP1 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.